Related Experiment Video
Updated: Jul 23, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells
Irem Dogan Turacli1, Funda Demirtas Korkmaz2, Tuba Candar3
1Department of Medical Biology, Faculty of Medicine, Ufuk University, Ankara, Turkey.
Background:
There is still no clinically approved agent for mutant KRAS, which is the most common alteration in non-small-cell lung cancer (NSCLC). Flavopiridol is a semisynthetic flavonoid that inhibits cell growth through cyclin-dependent kinases in G1/S or G2/M of the cell cycle and induces apoptosis. In this study, we evaluated its effect on cellular apoptosis, survival, and metastasis mechanisms on KRAS mutant A549, Calu-1, and H2009 cell lines.
Methods:
The cytotoxic effects of flavopiridol on NSCLC cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability test. The cells were treated with 200 and 400 nM flavopiridol, and, then, apoptosis, survival, and metastasis-related protein expressions were determined by Western blot analysis. The antimetastatic effects of flavopiridol were assessed by wound healing and Galectin-3 activity assay.
Results:
Flavopiridol drastically affected toxicity in all KRAS mutant NSCLC cells at nanomolar concentrations. Also, it could efficiently inhibit wound healing and Galectin-3 activity in all the cells tested. However, the metastasis-related protein expressions did not reflect these obvious effects on blotting. p-Erk was activated as a cellular survival mechanism to escape apoptosis in all the cells tested.
Conclusion:
Although there are many mechanisms that still need to be elucidated, flavopiridol can be used as a metastasis inhibitor and an apoptosis inducer in KRAS mutant NSCLC.
Insights
Flavopiridol effectively induces apoptosis and inhibits metastasis in KRAS-mutant non-small cell lung cancer (NSCLC) cells. This flavonoid shows promise as a therapeutic agent, despite some survival pathways being activated.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Mutant KRAS is a common driver in non-small cell lung cancer (NSCLC) with no current targeted therapies.
- Flavopiridol, a flavonoid, inhibits cell cycle progression and induces apoptosis.
- This study investigates flavopiridol's impact on KRAS-mutant NSCLC cell lines.
Purpose of the Study:
- To evaluate flavopiridol's efficacy in inducing apoptosis in KRAS-mutant NSCLC.
- To assess flavopiridol's effects on cancer cell survival mechanisms.
- To determine flavopiridol's potential as an anti-metastatic agent in NSCLC.
Main Methods:
- Cytotoxicity assessed using MTT assays.
- Apoptosis, survival, and metastasis-related protein expression analyzed via Western blot.
- Antimetastatic effects evaluated through wound healing and Galectin-3 activity assays.
Main Results:
- Flavopiridol demonstrated significant toxicity at nanomolar concentrations in KRAS-mutant NSCLC cells.
- Flavopiridol effectively inhibited cell migration (wound healing) and Galectin-3 activity.
- p-Erk activation was observed as a survival mechanism, counteracting apoptosis.
Conclusions:
- Flavopiridol exhibits potential as both an apoptosis inducer and a metastasis inhibitor in KRAS-mutant NSCLC.
- Further research is needed to fully elucidate the complex mechanisms involved.
- Flavopiridol represents a promising therapeutic candidate for KRAS-mutant NSCLC.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
07:59Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021